Somaxon Pharmaceuticals, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Somaxon Pharmaceuticals, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Somaxon Pharmaceuticals, Inc.. The Company's principal activity is that of licensing, development and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its product candidates are Silenor is in Phase 3 clinical trials for the treatment of insomnia, Nalmefene hydrochloride is in a Phase 2/3 clinical trial for the treatment of pathological gambling and a Phase 2 clinical trial for smoking cessation. The Company is also developing a new formulation of Acamprosate Calcium for the treatment of certain movement disorders.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report